Evaluating container closure integrity requires aligning test capabilities with specific package materials, product formulations, and lifecycle stages. While traditional probabilistic approaches like dye ingress have long served as industry baselines, deterministic technologies—such as vacuum decay, high-voltage leak detection (HVLD), and helium mass spectrometry—offer superior sensitivity, repeatability, and non-destructive testing capabilities.
Selecting the right methodology depends heavily on physical attributes: liquid conductivity dictates HVLD feasibility, gas headspace influences vacuum decay accuracy, and deep-cold storage requirements often necessitate the extreme sensitivity of tracer gas detection. A risk-based selection strategy balances these mechanical constraints against validation demands to ensure compliance and mitigate contamination risks.
Mastering these selection criteria ensures your package integrity strategy meets regulatory standards while protecting patient safety. Watch to build a deterministic CCIT framework tailored to your container system.
Originally released with Outsourced Pharma
Christian Collazo-Sara, BS BME, Manager - Container Closure Integrity, Medical Device, and Package Testing
Pace® Life Sciences – Lebanon, NJ
Christian Collazo-Sarra is a manager at the Pace® Life Sciences laboratory in Lebanon, NJ focusing on CCIT, drug delivery device functional characterization, and package distribution testing services. He has over 7 years of experience in contract testing across multiple disciplines in the pharmaceutical industry and is a graduate of Rutgers School of Engineering, with a BS in Biomedical Engineering.